Here’s a fresh analysis regarding the Q3 report:
The decline in revenue seen in Q3 came as a surprise, and in light of the company’s comments, achieving growth in Q4 will also be challenging. As a result, our previous assumption of a gradual recovery already in Q4’25-Q2’26 was cut, and this was reflected in a downward revision of revenue forecasts for the coming years. With weaker growth, the earnings leverage we previously expected will also be smaller. With the lowered forecasts, the stock’s valuation is no longer as attractive with 2026 multiples, and hopes for a more significant improvement in earnings shift to 2027, when stronger results from the Sarastia integration are also likely to start being seen. Visibility a few years out is still so weak that at this point, we remain on a waiting stance regarding the stock, monitoring profitability improvement and the Sarastia integration.